Keywords: medichem, gets, commercialization, rights, anti-hiv, calanolides, results

MediChem gets commercialization rights to anti-HIV calanolides

Article | 11 September 1995

Print This

The results of the PICO study of pimobendan in patients with chronic congestive heart failure may spell the end to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in